Abstract

Both the incidence and prevalence of inflammatory bowel disease (IBD) is increasing globally; in the industrialized world up to 0.5% of the population are affected and around 4.2 million individuals suffer from IBD in Europe and North America combined. Successful engraftment in experimental colitis models suggests that intestinal stem cell transplantation could constitute a novel treatment strategy to re‐establish mucosal barrier function in patients with severe disease. Intestinal stem cells can be grown in vitro in organoid structures, though only a fraction of the cells contained are stem cells with regenerative capabilities. Hence, techniques to enrich stem cell populations are being pursued through the development of multiple two‐dimensional and three‐dimensional culture protocols, as well as co‐culture techniques and multiple growth medium compositions. Moreover, research in support matrices allowing for efficient clinical application is in progress. In vitro culture is accomplished by modulating the signaling pathways fundamental for the stem cell niche with a suitable culture matrix to provide additional contact‐dependent stimuli and structural support. The aim of this review was to discuss medium compositions and support matrices for optimal intestinal stem cell culture, as well as potential modifications to advance clinical use in IBD.

Highlights

  • Both the incidence and prevalence of inflammatory bowel disease (IBD) is increasing globally; in the industrialized world up to 0.5% of the population are affected and around 4.2 million individuals suffer from IBD in Europe and North America combined

  • This review provides an updated overview of current growth protocols for human intestinal stem cells (ISCs) in vitro, seeking to pinpoint obstacles in stem cell enrichment and matrix support, which should be addressed to allow for regenerative application of ISCs in IBD

  • The canonical WNT pathway is activated by binding of a WNT ligand to the Frizzled receptor and its co-receptor complex low-density lipoprotein receptor-related protein 5/6 (LRP5/6)

Read more

Summary

Published Version Citable link Terms of Use

Fredrik EO, Jakob B Seidelin, Xiaolei Yin, Benjamin E Mead, Zhixiang Tong, Yuan Li, Jeffrey M Karp, and Ole H Nielsen. 2017. “Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease.”. Fredrik EO Holmberg, Jakob B Seidelin, Xiaolei Yin, Benjamin E Mead, Zhixiang Tong, Yuan Li1, Jeffrey M Karp2,3,4,5,6,7,* & Ole H Nielsen1,**

Introduction
EMBO Molecular Medicine
Growth medium
Effect on ISCs and application
Valproic acid Noggina
Target transcription factors and genes
Notch signaling
Culture matrices
Collagen IV
Regenerative applications in IBD
Well defined components
Intestinal stem cells are enriched as organoids
Future perspectives
Findings
Conflict of interest

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.